# Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy

> **NCT04263610** · PHASE4 · COMPLETED · sponsor: **Almirall, S.A.** · enrollment: 190 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Dimethyl fumarate (DMF) standard scheme
- **DRUG:** Dimethyl fumarate (DMF) simplified scheme
- **DRUG:** Tildrakizumab

## Key facts

- **NCT ID:** NCT04263610
- **Lead sponsor:** Almirall, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-04
- **Primary completion:** 2022-02-16
- **Final completion:** 2022-02-16
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2022-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04263610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04263610, "Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04263610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*